Tirzepatide by quarter
Coverage and results for Tirzepatide quarter by quarter. Read the supplier-count column beside the median: a quarter where the compound mix changed is not comparable with the one before it, and the index cannot hold that constant retrospectively.
| Quarter | Batches | Reports | Median purity % | IQR pp | Suppliers | Flagged | What changed in the index |
|---|---|---|---|---|---|---|---|
| 2024-Q1 | 2 | 6 | 98.55 | 0.64 | 2 | 0 | Backfill quarter. Reports assayed earlier were accepted retrospectively where custody could be documented. |
| 2024-Q2 | 6 | 45 | 98.22 | 0.55 | 4 | 10 | First quarter of live submission. |
| 2024-Q3 | 8 | 65 | 98.19 | 1.17 | 8 | 7 | Nordanalyt Laboratories began contributing. |
| 2024-Q4 | 5 | 39 | 98.49 | 0.96 | 4 | 17 | Impurity-fingerprint matching introduced; first shared-bulk links published. |
| 2025-Q1 | 11 | 96 | 98.95 | 0.67 | 6 | 28 | Anomaly rule set expanded from seven rules to eleven. |
| 2025-Q2 | 16 | 109 | 98.53 | 0.83 | 14 | 35 | Gravimetric mass-balance reconciliation became mandatory on new records. |
| 2025-Q3 | 15 | 103 | 98.23 | 0.90 | 13 | 28 | Kestrel Bioanalytical began contributing; gradient-length normalisation introduced. |
| 2025-Q4 | 8 | 61 | 99.02 | 0.94 | 6 | 31 | Provenance classification became a required field. |
| 2026-Q1 | 12 | 78 | 98.55 | 0.77 | 10 | 11 | Rule AX-R12 added. Dataset v2 schema published. |
| 2026-Q2 | 18 | 118 | 98.78 | 0.73 | 14 | 32 | Buyer-sourced sensitivity analysis added to every supplier scorecard. |
| 2026-Q3 | 4 | 30 | 97.81 | 1.18 | 4 | 4 | Quarter in progress. Aggregates for this quarter are provisional. |
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes. A trend across 11 points, most of them thin, is a shape and not a finding.